$MREO News

Mereo BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates

Mereo BioPharma Group Q1 EPS $(0.01), Inline

European Equities Traded in the US as American Depositary Receipts Start Week on Flat Note in Monday Trading

European Equities Traded in the US as American Depositary Receipts Higher in Tuesday Trading

We're Hopeful That Mereo BioPharma Group (NASDAQ:MREO) Will Use Its Cash Wisely

European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading

Mereo BioPharma Reports Full Year 2025 Financial Results and Provides Corporate Highlights

Mereo BioPharma Group Q4 EPS $(0.01), Inline

European Equities Traded in the US as American Depositary Receipts Little Changed in Tuesday Trading

European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading

BTIG Reiterates Buy on Mereo BioPharma Group, Maintains $1 Price Target

Mereo BioPharma Group (MREO) Is Up 74.4% After Mixed Setrusumab Phase 3 Data and Cash Update – Has The Bull Case Changed?

A Look At Mereo BioPharma (MREO) Valuation After Mixed Setrusumab Phase 3 Update And Conference Spotlight

Mereo BioPharma Group plc (MREO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Mereo BioPharma Group plc (MREO) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow

Needham Maintains Buy on Mereo BioPharma Group, Lowers Price Target to $3

European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading

Mereo BioPharma Provides Corporate Update

European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading

European Equities Traded in the US as American Depositary Receipts Track Lower in Wednesday Trading